Iguana Healthcare Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Iguana Healthcare Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-75,000	Closed	-$5.08M	–	63
2016 Q3	$5.08M	Buy	75,000 +50,000	+200%	+$3.53M	1.81%	18
2016 Q2	$1.39M	Sell	25,000 -35,000	-58%	-$2.21M	0.56%	57
2016 Q1	$3.77M	Buy	60,000 +35,000	+140%	+$2.33M	1.38%	24
2015 Q4	$2.35M	Buy	25,000 +10,000	+67%	+$927K	0.77%	38
2015 Q3	$1.21M	Buy	+15,000	New	+$1.67M	0.47%	52

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Iguana Healthcare Management's ALNY Position: Q4 2016 in Review

Iguana Healthcare Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 75,000 shares — an estimated $5.08M sold.

Iguana Healthcare Management first reported a position in ALNY in Q3 2015 and held it in 5 quarters. The position peaked at $5.08M in Q3 2016. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Iguana Healthcare Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Iguana Healthcare Management sold 75,000 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $5.08M.
Iguana Healthcare Management first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Iguana Healthcare Management's Alnylam Pharmaceuticals position peaked at $5.08M in Q3 2016.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Iguana Healthcare Management's 13F filing for Q4 2016, filed 14 Feb 2017.